Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
breast cancer - HER2-positive, ... vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results SOPHIA, 2021 (REV) 1.12 [0.88; 1.44]
SYSUCC-002, 2022 (REV) 1.22 [0.96; 1.54]
1.17 [0.99 ; 1.39 ] SOPHIA, 2021 (REV), SYSUCC-002, 2022 (REV) 2 0% 928 moderate not evaluable progression or deaths (PFS)detailed results SOPHIA, 2021 (REV) 1.32 [1.02; 1.70]
SYSUCC-002, 2022 (REV) 1.14 [0.92; 1.41]
1.21 [1.03 ; 1.42 ] SOPHIA, 2021 (REV), SYSUCC-002, 2022 (REV) 2 0% 928 moderate not evaluable objective responses (ORR)detailed results SOPHIA, 2021 (REV) 0.67 [0.43; 1.04]
0.67 [0.43 ; 1.04 ] SOPHIA, 2021 (REV) 1 0% 524 NA not evaluable Abdominal pain AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.74 [0.16; 3.35]
0.74 [0.16 ; 3.35 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Alopecia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.99 [0.02; 50.21]
0.99 [0.02 ; 50.21 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Anaemia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 1.32 [0.63; 2.77]
1.32 [0.63 ; 2.77 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Arthralgia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 1.99 [0.07; 59.54]
1.99 [0.07 ; 59.54 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Asthenia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.82 [0.25; 2.73]
0.82 [0.25 ; 2.73 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Constipation AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.99 [0.14; 7.10]
0.99 [0.14 ; 7.10 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Cough AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.50 [0.02; 14.83]
0.50 [0.02 ; 14.83 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Decreased appetite AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.99 [0.06; 15.95]
0.99 [0.06 ; 15.95 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Diarrhoea AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.99 [0.32; 3.12]
0.99 [0.32 ; 3.12 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Dizziness AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.50 [0.02; 14.83]
0.50 [0.02 ; 14.83 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Dyspnoea AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 2.01 [0.50; 8.11]
2.01 [0.50 ; 8.11 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Fatigue AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.60 [0.24; 1.47]
0.60 [0.24 ; 1.47 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 1.64 [0.67; 4.04]
1.64 [0.67 ; 4.04 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Headache AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.99 [0.02; 50.21]
0.99 [0.02 ; 50.21 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Hypertension AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.39 [0.08; 2.04]
0.39 [0.08 ; 2.04 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Increase AST AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.42 [0.11; 1.64]
0.42 [0.11 ; 1.64 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Increased ALT AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.79 [0.21; 2.98]
0.79 [0.21 ; 2.98 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.12 [0.01; 2.33]
0.12 [0.01 ; 2.33 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Leucopenia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.25 [0.03; 2.21]
0.25 [0.03 ; 2.21 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 1.99 [0.07; 59.54]
1.99 [0.07 ; 59.54 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Nausea AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.33 [0.03; 3.18]
0.33 [0.03 ; 3.18 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Neutropenia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.58 [0.36; 0.93]
0.58 [0.36 ; 0.93 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 3.00 [0.31; 29.03]
3.00 [0.31 ; 29.03 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Pneumonia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 3.02 [0.60; 15.12]
3.02 [0.60 ; 15.12 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Pyrexia AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.99 [0.06; 15.95]
0.99 [0.06 ; 15.95 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Stomatitis AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable Vomiting AE (grade 3-4)detailed results SOPHIA, 2021 (REV) 2.00 [0.36; 11.01]
2.00 [0.36 ; 11.01 ] SOPHIA, 2021 (REV) 1 0% 530 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-01 14:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 336,147,145,355,337,146,317
- treatments: 1305
